Financial Results for FY2026 Second Quarter

(April 1, 2026 – September 30, 2026)

November 2, 2026

SUMITOMO CHEMICAL

(Cautionary Statement)

Statements made in this material with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

Contents

1. Consolidated Financial Results for FY2026 Second Quarter

Summary for FY2026 First Half ····· 4
Consolidated Financial Results Summary····· 5
Sales Revenue by Reporting Segment ····· 6
Core Operating Income by Reporting Segment ··· 7
Core Operating Income Analysis by Reporting Segment ····· 8
Consolidated Statement of Financial Position ···· 13
Consolidated Statement of Cash Flows····· 14

2. Outlook for FY2026

Outlook for the Business Environment ····· 16
Summary of the Financial Forecast for FY2026 ····· 17
Performance Forecast for FY2026 ····· 18
Sales Revenue and Core Operating Income by Reporting Segment ····· 19

(Reference)

Sales Revenue by Reporting Segment (Quarterly) ····· 21
Core Operating Income by Reporting Segment (Quarterly) ····· 22
Sales Revenue Analysis by Reporting Segment ····· 23
Cost and other Elements ····· 28
Cost and other Elements by Reporting Segment ····· 29
Major Group Companies ····· 30
Crop Protection Product Sales by Region ····· 31

1. Consolidated Financial Results for FY2026 Second Quarter

Summary for FY2026 First Half

Core Operating Income

(Billions of yen)

Q2 FY2025	Q2 FY2026	FY2026 Forecast (announced in Aug.)
108.7	**144.5**	125.0
※Excluding gains on sale of businesses		
approx. 50.0	**approx. 135.0**	approx. 120.0

Net Income Attributable to Owners of the Parent

(Billions of yen)

Q2 FY2025	Q2 FY2026	FY2026 Forecast (announced in Aug.)
39.7	**82.9**	70.0

- **Core operating income and net income attributable to owners of the parent increased significantly from the same period of the prior year and exceeded the forecast announced in August**
- The Group's first-half results for FY2026 were its **second-highest first-half results on record**

- **Core operating income**
  - **ICT & Mobility Solutions:** Although shipments of display-related materials decreased amid semiconductor shortages, shipments of **semiconductor processing materials** increased
  - **Agro & Life Solutions:** Although business conditions for **crop protection products outside Japan** have been slow to recover, shipments for **crop protection products inside of Japan** have remained steady and profit margins for **feed additives** have improved
  - **Essential & Green Materials:** **Petro Rabigh's** financial results improved due to the situation in the Middle East, while temporary inventory valuation gains also significantly boosted core operating income

- **The D/E ratio improved significantly from 0.93 times at the end of March 2026 to 0.73 times**, due to solid performance and Sumitomo Pharma's capital increase of 97.8 billion yen

Consolidated Financial Results Summary

(Billions of yen)

	Q2 FY2026	Q2 FY2025	Variance	Variance Ratio
Sales revenue	**1,172.8**	1,095.4	77.4	7.1%
Core operating income	**144.5**	108.7	35.8	32.9%
of which equity-method investments	**36.7**	(27.3)	64.0	-
Total non-recurring items (breakdown below)	**(6.5)**	(5.0)	(1.4)	-
Restructuring costs	**(5.0)**	(3.5)	(1.5)	-
Impairment losses	**(4.2)**	(3.3)	(0.9)	-
Others	**2.7**	1.8	0.9	-
Operating income	**138.1**	103.7	34.4	33.2%
Finance income/expenses (breakdown below)	**(16.1)**	(15.8)	(0.3)	-
(Loss) on foreign currency transactions including gain (loss) on derivatives	**(9.4)**	(6.4)	(3.0)	-
Others	**(6.7)**	(9.4)	2.7	-
Income before taxes	**121.9**	87.9	34.0	38.7%
Income tax expenses	**(16.3)**	3.0	(19.3)	-
Net income	**105.7**	90.9	14.7	16.2%
Net (income) attributable to non-controlling interests	**(22.8)**	(51.2)	28.5	-
Net income attributable to owners of the parent	**82.9**	39.7	43.2	108.8%
ROE	**7.6%**	4.3%		
Exchange rate (yen/$)	**159.49**	146.02		
Naphtha price (yen/kl)	**107,500**	64,800		
Overseas sales revenue ratio	**68.2%**	70.0%		


Sales Revenue by Reporting Segment

(Billions of yen)

	Q2 FY2026	Q2 FY2025	Variance	Variance Ratio	Sales price variance	Shipping volume variance	Foreign currency (FX) conversion variance
Agro & Life Solutions	**226.5**	213.0	13.5	6.4%	15.0	(15.3)	13.8
ICT & Mobility Solutions	**311.9**	283.5	28.4	10.0%	7.0	4.4	17.1
Advanced Medical Solutions	**21.5**	21.1	0.3	1.6%	0.0	0.3	0.1
Essential & Green Materials	**320.9**	329.1	(8.3)	(2.5)%	63.5	(81.2)	9.4
Sumitomo Pharma *	**265.5**	226.1	39.4	17.4%	(1.5)	23.2	17.8
Others	**26.5**	22.6	3.9	17.5%	0.0	3.9	0.0
Total	**1,172.8**	1,095.4	77.4	7.1%	84.0	(64.7)	58.1

*The regenerative medicine and cellular therapy CDMO business does not fall under this segment. Therefore, sales revenue differs between this segment and Sumitomo Pharma Co., Ltd.

Variance analysis




Core Operating Income by Reporting Segment

(Billions of yen)

	Q2 FY2026	Q2 FY2025	Variance	Price variance	Cost variance	Shipping volume variance and other
Agro & Life Solutions	**20.8**	11.2	9.6	11.0	0.0	(1.4)
ICT & Mobility Solutions	**31.9**	33.1	(1.2)	(4.5)	(3.0)	6.3
Advanced Medical Solutions	**(3.7)**	(1.4)	(2.3)	(1.0)	0.0	(1.3)
Essential & Green Materials	**62.1**	(18.6)	80.7	13.5	3.5	63.7
Sumitomo Pharma *	**43.6**	97.3	(53.8)	(1.5)	(5.0)	(47.3)
Others & Adjustments	**(10.2)**	(13.0)	2.8	0.0	0.0	2.8
Total	**144.5**	108.7	35.8	17.5	(4.5)	22.8

*The regenerative medicine and cellular therapy CDMO business does not fall under this segment. Therefore, core operating income differs between this segment and Sumitomo Pharma Co., Ltd.

Variance analysis



Core Operating Income Analysis by Reporting Segment

Agro & Life Solutions

Total ¥ 20.8 billion ¥ 9.6 billion from Q2 FY2025




Crop Protection	→ Slow recovery in business environment outside of Japan (Price(-))
Feed Additives	↗ Improvement in profit margins (Price(+)) Decrease in demand (Volume and other(-))

Core Operating Income Analysis by Reporting Segment

ICT & Mobility Solutions

Total ¥ 31.9 billion ¥ (1.2) billion from Q2 FY2025



Displays	↘	Absence of prior year gain on the sale of the large LCD polarizing film business (Volume and other(-)) Decline in mobile related shipments due to a shortage of semiconductors (Volume and other(-)) Decline in the selling prices of polarizing films (Price(-))
Semiconductors	↗	Increase in shipments due to growing demand for semiconductors (Volume and other(+)) Increase in fixed costs due to acquisitions and capacity expansion (Cost(-))
Mobility	↗	Increase in shipments of super engineering plastics (Volume and other(+))

Core Operating Income Analysis by Reporting Segment

Advanced Medical Solutions

Total ¥ (3.7) billion ¥ (2.3) billion from Q2 FY2025




Difference in sales mix of active pharmaceutical ingredients and intermediates (Volume and other(-))
Decline in profit margins due to the Middle East geopolitical tensions (Price(-))

Core Operating Income Analysis by Reporting Segment

Essential & Green Materials

Total ¥ 62.1 billion ¥ 80.7 billion from Q2 FY2025




Japan	Inventory valuation gains (Price(+))
Singapore	Inventory valuation gains (Price(+))
Saudi Arabia	Impact of prior year shutdown maintenance and improvement in refining margins (Volume and other(+))

Core Operating Income Analysis by Reporting Segment

Sumitomo Pharma

Total ¥ 43.6 billion ¥ (53.8) billion from Q2 FY2025



Partial sale of the Asian business in the prior year (Volume and other(-), Cost(+))
Increase in selling, general, and administrative expenses, and R&D expenses in North America (Cost(-))
Growth in sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and GEMTESA® (treatment for overactive bladder) (Volume and other(+))

Consolidated Statement of Financial Position

(Billions of yen)

	30-Sep-26	31-Mar-26	Variance
Current assets	**1,623.0**	1,507.7	115.3
Cash and cash equivalents	**208.4**	208.6	(0.2)
Trade and other receivables	**637.0**	608.7	28.3
Inventories	**653.4**	595.5	57.9
Others	**124.2**	95.0	29.2
Non-current assets	**2,003.1**	1,897.3	105.7
Property, plant and equipment	**772.7**	770.7	2.0
Goodwill and intangible assets	**491.0**	501.0	(10.1)
Others	**739.4**	625.6	113.8
Total	**3,626.1**	3,405.0	221.0

	30-Sep-26	31-Mar-26	Variance
Liabilities	**2,143.5**	2,168.4	(24.9)
Trade and other payables	**529.8**	464.4	65.4
Interest-bearing liabilities	**1,087.4**	1,151.5	(64.1)
Others	**526.3**	552.5	(26.2)
Equity	**1,482.6**	1,236.7	246.0
Shareholders' equity	**858.3**	744.9	113.4
Other components of equity	**307.0**	263.8	43.3
Non-controlling interests	**317.3**	228.0	89.3
Total	**3,626.1**	3,405.0	221.0
Ratio of equity attributable to owners of the parent to total	**32.1%**	29.6%	2.5%
D/E ratio (times)	**0.73**	0.93	(0.20)

Consolidated Statement of Cash Flows

(Billions of yen)

	Q2 FY2026	Q2 FY2025	Variance
Cash flows from operating activities	**66.6**	57.7	8.9
Cash flows from investing activities	**(84.9)**	(16.7)	(68.2)
Free cash flows	**(18.3)**	41.0	(59.3)
Cash flows from financing activities	**16.0**	(114.8)	130.8
Others	**2.2**	2.9	(0.8)
Increase (decrease) in cash and cash equivalents	**(0.2)**	(70.9)	70.7
Cash and cash equivalents at the end of the period	**208.4**	161.2	47.2

2. Outlook for FY2026

Outlook for the Business Environment

Economic Conditions


- Although growth in the field of technology is firmly supporting the global economy, future prospects remain uncertain due to geopolitical risks, including tensions in the Middle East.

Business Environment

Crop Protection		There has been a delay in recovery in the business environment for crop protection products outside of Japan.
Feed Additives		Although profit margins saw temporary improvement in the first half, the outlook for the second half and beyond remains uncertain.
Displays		The mobile device market will remain sluggish due to the increasingly challenging procurement conditions for memory chips and other components.
Semiconductors		Demand for silicon semiconductors will remain solid, mainly driven by AI-related areas.
Petrochemicals/ Raw Materials		Enough raw materials have been secured to meet current production plans, but the impact of high raw material prices will continue for the time being.

Summary of the Financial Forecast for FY2026

Forecast for FY2026



※Excluding impact of the timing difference in the partial sale of shares in Petro Rabigh in FY2025

Core operating income: projected to be 270.0 billion yen, an upward revision from 215.0 billion yen
Net income attributable to owners of the parent: projected to reach 90.0 billion yen, an upward revision from 70.0 billion yen
Year-end dividend: projected at 9 yen, an upward revision from 8 yen

- **Core operating income is expected to be the largest in the Group's history**
- Core operating income in **ICT & Mobility Solutions** is projected to increase from 55 billion yen to **60 billion yen** due to an increase in shipments of semiconductor processing materials
- Core operating income in **Essential & Green Materials** is expected to significantly increase from 20 billion yen to **75 billion yen** due to Petro Rabigh's financial results improving as a result of the situation in the Middle East and temporary inventory valuation gains
- Core operating income in **Sumitomo Pharma** is projected to increase from 94 billion yen to **108 billion yen** due to strong sales of GEMTESA®
- **The annual dividend has been revised upward to 17 yen** (13.5 yen in FY2025)

Performance Forecast for FY2026

(Billions of yen)

		Revised forecast	Previous forecast (announced in May)	Variance	Variance ratio	FY2025 actual
Sales revenue		**2,490.0**	2,360.0	130.0	5.5%	2,328.5
Core operating income		**270.0**	215.0	55.0	25.6%	208.4
Non-recurring items		**(55.0)**	(38.0)	(17.0)	-	(56.6)
Operating income		**215.0**	177.0	38.0	21.5%	151.7
Net income attributable to owners of the parent		**90.0**	70.0	20.0	28.6%	60.9
ROE		**8.6%**	6.8%			6.4%
Exchange rate (yen/$)		**157.00 (2nd Half 155.00)**	155.00 (2nd Half 155.00)			150.67
Naphtha price (yen/kl)		**99,000 (2nd Half 90,000)**	92,000 (2nd Half 92,000)			65,200
Cash dividends (yen)	Interim dividend	**8.00**	8.00			6.00
	Year-end dividend	**9.00**	8.00			7.50
	Annual dividend	**17.00**	16.00			13.50

Sales Revenue and Core Operating Income by Reporting Segment

(Billions of yen)

		Revised forecast	Previous forecast (announced in May)	Variance	FY2025 actual
Agro & Life Solutions	Sales Revenue	**570.0**	560.0	10.0	519.3
	Core Operating Income	**65.0**	65.0	-	56.3
ICT & Mobility Solutions	Sales Revenue	**610.0**	590.0	20.0	574.2
	Core Operating Income	**60.0**	55.0	5.0	53.0
Advanced Medical Solutions	Sales Revenue	**60.0**	60.0	-	58.6
	Core Operating Income	**3.0**	3.0	-	2.8
Essential & Green Materials	Sales Revenue	**630.0**	560.0	70.0	678.8
	Core Operating Income	**75.0**	20.0	55.0	14.4
Sumitomo Pharma	Sales Revenue	**565.0**	540.0	25.0	451.9
	Core Operating Income	**108.0**	94.0	14.0	108.4
Others	Sales Revenue	**55.0**	50.0	5.0	45.8
	Core Operating Income	**(41.0)**	(22.0)	(19.0)	(26.7)
Total	Sales Revenue	**2,490.0**	2,360.0	130.0	2,328.5
	Core Operating Income	**270.0**	215.0	55.0	208.4
	"Excluding gains on sale of businesses"	**approx. 260.0**	approx. 210.0		approx. 120.0

(Reference)

Sales Revenue by Reporting Segment (Quarterly)

(Billions of yen)

	FY2025				FY2026			
	Q1	Q2	Q3	Q4	Q1	Q2	1st Half	2nd Half (Forecast)
Agro & Life Solutions	96.9	116.1	133.9	172.4	109.0	117.5	226.5	343.5
ICT & Mobility Solutions	137.4	146.1	148.3	142.4	148.6	163.3	311.9	298.1
Advanced Medical Solutions	9.1	12.1	14.5	23.0	10.4	11.1	21.5	38.5
Essential & Green Materials	165.4	163.8	181.8	167.8	170.2	150.7	320.9	309.1
Sumitomo Pharma	107.4	118.7	120.3	105.5	129.0	136.5	265.5	299.5
Others	10.0	12.6	12.1	11.1	11.0	15.5	26.5	28.5
Total	526.1	569.3	610.9	622.2	578.2	594.6	1,172.8	1,317.2

Core Operating Income by Reporting Segment (Quarterly)


(Billions of yen)

	FY2025				FY2026			
	Q1	Q2	Q3	Q4	Q1	Q2	1st Half	2nd Half (Forecast)
Agro & Life Solutions	2.2	9.0	16.9	28.2	9.6	11.2	20.8	44.2
ICT & Mobility Solutions	18.4	14.7	13.4	6.5	13.0	18.9	31.9	28.1
Advanced Medical Solutions	(1.0)	(0.4)	1.7	2.5	(1.9)	(1.8)	(3.7)	6.7
Essential & Green Materials	(5.5)	(13.1)	38.4	(5.3)	27.2	34.9	62.1	12.9
Sumitomo Pharma	21.0	76.3	13.9	(2.8)	18.8	24.8	43.6	64.4
Others & Adjustments	(7.4)	(5.5)	(6.2)	(7.6)	(4.5)	(5.7)	(10.2)	(30.8)
Total	27.7	81.0	78.1	21.5	62.3	82.2	144.5	125.5

Sales Revenue Analysis by Reporting Segment

Agro & Life Solutions

Total ¥ 226.5 billion ¥ 13.5 billion from Q2 FY2025




Crop Protection	→	Weaker yen's effect on the sales of subsidiaries outside Japan when converted into yen (FX(+)) Slow recovery in business environment outside of Japan (Price(-)) Sale of domestic subsidiary in prior year (Volume(-))
Feed Additives	↗	Improvement in product market conditions (Price(+)) Decrease in demand (Volume(-))

Sales Revenue Analysis by Reporting Segment

ICT & Mobility Solutions

Total ¥ 311.9 billion ¥ 28.4 billion from Q2 FY2025




Displays	↘	Decline in mobile related shipments due to a shortage of semiconductors (Volume(-)) Decline in the selling prices of polarizing films (Price(-)) Absence of prior year sales due to the divestiture of the large LCD polarizing film business (Volume(-))
Semiconductors	↗	Increase in shipments due to growing demand (Volume(+)) Increase in selling prices (Price(+))
Mobility	↗	Improvement in resorcinol product market conditions (Price(+))

Sales Revenue Analysis by Reporting Segment

Advanced Medical Solutions

Total ¥ 21.5 billion ¥ 0.3 billion from Q2 FY2025




Difference in shipments timing for active pharmaceutical ingredients and intermediates (Volume(+))

Sales Revenue Analysis by Reporting Segment

Essential & Green Materials

Total ¥ 320.9 billion ¥ (8.3) billion from Q2 FY2025




Japan	↗ Increase in raw material and product market prices (Price(+))
Singapore	↘ Decline in capacity utilization rate due to the Middle East geopolitical tensions (Volume(-)) Decrease in shipments due to the transfer of sales rights for Petro Rabigh products (Volume(-)) Increase in raw material and product market prices (Price(+))

Sales Revenue Analysis by Reporting Segment

Sumitomo Pharma

Total ¥ 265.5 billion **¥ 39.4 billion from Q2 FY2025**



Increase in sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and GEMTESA® (treatment for overactive bladder) (Volume(+))
Partial sale of the Asian business in the prior year (Volume(-))

Cost and other Elements

(Billions of yen)

	Q2 FY2026	Q2 FY2025	Variance
Capital Expenditures	**52.1**	58.0	(5.9)
Depreciation and Amortization	**59.1**	60.0	(0.8)
Research & Development Expenses	**74.3**	67.0	7.3
Number of Employees (as of September 30)	**26,972**	27,699	(727)

Cost and other Elements by Reporting Segment

(Billions of yen)

	Capital Expenditures		Depreciation& Amortization		R&D Expenses	
	Q2 FY2026	Q2 FY2025	Q2 FY2026	Q2 FY2025	Q2 FY2026	Q2 FY2025
Agro & Life Solutions	**7.8**	7.1	**10.9**	10.1	**16.9**	14.9
ICT & Mobility Solutions	**20.8**	26.3	**18.2**	16.3	**18.2**	16.3
Advanced Medical Solutions	**3.9**	5.7	**3.8**	3.9	**2.1**	2.0
Essential & Green Materials	**12.2**	6.7	**7.4**	10.1	**2.8**	4.0
Sumitomo Pharma	**3.2**	4.4	**9.8**	10.5	**24.0**	17.5
Others	**4.2**	7.8	**9.0**	9.1	**10.3**	12.3
Total	**52.1**	58.0	**59.1**	60.0	**74.3**	67.0

Major Group Companies

Company	Sales Revenue		Profit	
	Q2 FY2026	Q2 FY2025		
The Polyolefin Company (Singapore) (Millions of USD)	**377**	**390**	↗	Inventory valuation gains
PCS (Millions of USD)	**929**	**1,115**	↗	Inventory valuation gains
Rabigh Refining and Petrochemical Company (Millions of SAR)	**35,217**	**15,544**	↗	Impact of prior year shutdown maintenance and improvement in refining margins
Dongwoo Fine-Chem (Billions of KRW)	**1,074.1**	**1,028.3**	↗	Increase in profit driven by the semiconductor business
Sumitomo Chemical Brasil Indústria Química S.A. (Millions of BRL)	**1,307**	**1,416**	↘	Slow recovery in business environment
Sumitomo Biorational Company (Millions of USD)	**340**	**371**	↘	Delay in sales timing

Crop Protection Product Sales by Region

(Billions of yen)

	Q2 FY2026	Q2 FY2025	Variance	Reasons for Change
Japan	**32.7**	34.0	(1.3)	
North America	**18.1**	21.2	(3.1)	• Decrease in shipments due to delayed sales
Central & South America	**48.5**	44.1	4.4	• Increase in revenue due to foreign currency conversion variance, etc., despite a delay in recovery in the business environment
Asia (including India)	**36.6**	35.9	0.7	
Europe & Others	**14.1**	14.8	(0.7)	
Total	**150.0**	150.0	0.0	

※ Following the reorganization of our US biorationals business in April 2026, certain products were reclassified between the crop protection business and environmental health business. The results for Q2 FY2025 have been adjusted to reflect this change.